First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

PURPOSE: The first-in-human phase I/II ICONIC trial evaluated an investigational inducible costimulator (ICOS) agonist, vopratelimab, alone and in combination with nivolumab in patients with advanced solid tumors. PATIENTS AND METHODS: In phase I, patients were treated with escalating doses of intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Timothy A., Gainor, Justin F., Callahan, Margaret K., Falchook, Gerald S., Pachynski, Russell K., LoRusso, Patricia, Kummar, Shivaani, Gibney, Geoffrey T., Burris, Howard A., Tykodi, Scott S., Rahma, Osama E., Seiwert, Tanguy Y., Papadopoulos, Kyriakos P., Blum Murphy, Mariela, Park, Haeseong, Hanson, Amanda, Hashambhoy-Ramsay, Yasmin, McGrath, Lara, Hooper, Ellen, Xiao, Xiaoying, Cohen, Heather, Fan, Martin, Felitsky, Daniel, Hart, Courtney, McComb, Rachel, Brown, Karen, Sepahi, Ali, Jimenez, Judith, Zhang, Weidong, Baeck, Johan, Laken, Haley, Murray, Richard, Trehu, Elizabeth, Harvey, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433959/
https://www.ncbi.nlm.nih.gov/pubmed/35511938
http://dx.doi.org/10.1158/1078-0432.CCR-21-4256

Ejemplares similares

Ejemplares similares